Increased Excretion of Urinary N-Acetyl-β-Glucosaminidase in Essential Hypertension and Its Decline with Antihypertensive Therapy
Authors:
- Michael H. AldermanMAMichael H. Alderman
- Laurie MelcherLMLaurie Melcher
- Dennis E. DrayerDDDennis E. Drayer
- Marcus M. ReidenbergMRMarcus M. Reidenberg
- 17 November 1983
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 309 (20) , 1213-1217
Abstract
The urinary excretion of N-acetyl-β-glucosaminidase (NAG) is increased in patients whose renal function is impaired by a variety of kidney diseases, and may provide an index of renal injury. To assess its role in essential hypertension, we measured urinary levels of NAG in 80 subjects with essential hypertension (and no evidence of renal disease) and 30 normal controls. NAG values were measured before therapy and after 3 and 12 months of treatment with diuretics.Keywords
This publication has 12 references indexed in Scilit:
- Salicylate-induced enzymuriaThe American Journal of Medicine, 1978
- N-ACETYL-$beta;-D-GLUCOSAMINIDASE: A NEW APPROACH TO THE SCREENING OF HYPERTENSIVE PATIENTS FOR RENAL DISEASEThe Lancet, 1978
- Detection of renal artery stenosis by measuring urinary N-acetyl-beta-D-glucosaminidase.BMJ, 1978
- Urinary N-acetyl- beta-D-glucosaminidase activities in patients with renal disease.BMJ, 1975
- Detection and Treatment of Hypertension at the Work SiteNew England Journal of Medicine, 1975
- Automated assay of N-acetyl-β-GLucosaminidase in normal and pathological human urineClinica Chimica Acta, 1975
- Early Warning of Rejection?BMJ, 1973
- Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg1970
- The excretion of and β-galactosidase by patients with renal diseaseClinica Chimica Acta, 1970
- Studies on glucosaminidase. 4. The fluorimetric assay of N-acetyl-β-glucosaminidaseBiochemical Journal, 1961